Details for Patent: 11,234,976
✉ Email this page to a colleague
Which drugs does patent 11,234,976 protect, and when does it expire?
Patent 11,234,976 protects PYRUKYND and is included in one NDA.
This patent has twenty-seven patent family members in twenty countries.
Summary for Patent: 11,234,976
| Title: | Methods of using pyruvate kinase activators |
| Abstract: | Described herein are methods for using compounds that activate pyruvate kinase. |
| Inventor(s): | Samuel V. AGRESTA, Yue Chen, Marvin B. Cohen, Lenny Dang, Charles Kung, Elizabeth A. Merica, Bruce A. Silver, Hua Yang |
| Assignee: | MBC PHARMA SOLUTIONS, LLC , Agios Pharmaceuticals Inc |
| Application Number: | US15/735,036 |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for patent 11,234,976 |
|
Patent Claim Types: see list of patent claims | Use; Composition; |
Drugs Protected by US Patent 11,234,976
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Agios Pharms Inc | PYRUKYND | mitapivat sulfate | TABLET;ORAL | 216196-001 | Feb 17, 2022 | RX | Yes | No | 11,234,976 | ⤷ Start Trial | METHOD OF USING A PYRUVATE KINASE ACTIVATOR FOR THE TREATMENT OF HEMOLYTIC ANEMIA IN ADULTS WITH PYRUVATE KINASE (PK) DEFICIENCY BY ADMINISTERING A DAILY DOSE OF 10MG TO 100MG | ⤷ Start Trial | ||||
| Agios Pharms Inc | PYRUKYND | mitapivat sulfate | TABLET;ORAL | 216196-002 | Feb 17, 2022 | RX | Yes | No | 11,234,976 | ⤷ Start Trial | METHOD OF USING A PYRUVATE KINASE ACTIVATOR FOR THE TREATMENT OF HEMOLYTIC ANEMIA IN ADULTS WITH PYRUVATE KINASE (PK) DEFICIENCY BY ADMINISTERING A DAILY DOSE OF 10MG TO 100MG | ⤷ Start Trial | ||||
| Agios Pharms Inc | PYRUKYND | mitapivat sulfate | TABLET;ORAL | 216196-003 | Feb 17, 2022 | RX | Yes | Yes | 11,234,976 | ⤷ Start Trial | METHOD OF USING A PYRUVATE KINASE ACTIVATOR FOR THE TREATMENT OF HEMOLYTIC ANEMIA IN ADULTS WITH PYRUVATE KINASE (PK) DEFICIENCY BY ADMINISTERING A DAILY DOSE OF 10MG TO 100MG | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
Foreign Priority and PCT Information for Patent: 11,234,976
| PCT Information | |||
| PCT Filed | June 10, 2016 | PCT Application Number: | PCT/US2016/036893 |
| PCT Publication Date: | December 15, 2016 | PCT Publication Number: | WO2016/201227 |
International Family Members for US Patent 11,234,976
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Australia | 2016276951 | ⤷ Start Trial | |||
| Australia | 2021200060 | ⤷ Start Trial | |||
| Canada | 2989111 | ⤷ Start Trial | |||
| Denmark | 3307271 | ⤷ Start Trial | |||
| European Patent Office | 3307271 | ⤷ Start Trial | |||
| European Patent Office | 4344703 | ⤷ Start Trial | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
